Accordingly, inhibiting geminin Y150 phosphorylation (i.e. using imatinib), HMGB1 secretion or binding to RAGE or CXCR4 activity inhibited survival of GemOE tumor cells, recruitment of MSCs in vitro and in vivo into GemOE/TNBC tumors’ core and significantly reduced the aggressive traits of GemOE/TNBC cells. This evidence concerns the gene GMNN and neoplasm.